Overview

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Status:
Terminated
Trial end date:
2020-07-17
Target enrollment:
Participant gender:
Summary
This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center